Sonnet BioTherapeutics Holdings Return on Equity

Sonnet BioTherapeutics Holdings (SONN) currently reports a ROE of -149.36%. That is below the Consumer Staples sector average of 13.7%. Use the charts on this page to explore Sonnet BioTherapeutics Holdings's ROE history and peer comparisons.

Sonnet BioTherapeutics Holdings's ROE of -149.36% is lower than the Consumer Staples sector average of 13.7%. That is roughly 1190.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Sonnet BioTherapeutics Holdings's current -149.36% should be judged against Consumer Staples norms (sector average: 13.7%) and against SONN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -149.36%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Consumer Staples average is 13.7%. From there, open related valuation or income-statement pages for Sonnet BioTherapeutics Holdings, and consider following SONN for alerts when major investors trade the stock.

Sonnet BioTherapeutics Holdings is classified in the Consumer Staples sector. On ROE, it currently shows -149.36% versus a sector average near 13.7%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Consumer Staples are usually more informative than comparing SONN with unrelated industries.